Growth Factor News and Research

RSS

Study shows plexiform lesion develops in experimental rat model of severe PAH

A new preclinical model of pulmonary arterial hypertension may lead to improved research and ultimately better therapies for this life-threatening problem, according to its developers, researchers at the University of South Alabama.

20 May 2010

Plastic corneal prosthesis for patients unable to tolerate donor corneas

For many patients who become blind after an accident or illness, a corneal transplantation could restore the ability to see. Each year, 40,000 people in Europe - in Germany, about 7,000 - await the opportunity to be able to see again, thanks to cornea donors. But donor corneas are not common. Dr. Joachim Storsberg of the Fraunhofer Institute for Applied Polymer Research IAP in Potsdam-Golm developed material and production process for a corneal prosthesis made of plastic.

19 May 2010

Woman with higher blood levels of IGF-I more likely to develop breast cancer: Study

Women who have high blood levels of a hormone called insulin-like growth factor-I are more likely to develop breast cancer, according to a Cancer Research UK study published in the Lancet Oncology today (Monday).

18 May 2010

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

FibroGen, Inc. today announced that administration of investigational therapy FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), reversed the process of fibrosis in a preclinical model of radiation-induced lung fibrosis, a finding that has implications for treating multiple types of fibrotic disease.

18 May 2010

Researchers identify protein involved in pushing bladder tumors to become invasive

Bladder cancer often becomes aggressive and spreads in patients despite treatment, but now researchers at the Kimmel Cancer Center at Jefferson have identified a protein they believe is involved in pushing tumors to become invasive - and deadly.

15 May 2010

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.

14 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

Merck hosts R&D and Business Briefing

Merck & Co., Inc. today hosted its first R&D and Business Briefing since the completion of the Merck and Schering-Plough merger. The event included a comprehensive review of the company's late-stage pipeline, as well as the company's commercial strategy and progress made in the integration of Merck's worldwide operations.

12 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

Limiting fat intake to below 20% can reduce risk of breast cancer recurrence by 24%

When one of the country's foremost physicians—people like Dr. Andrew Weil—need someone to care for their friends and family dealing with cancer, the man they turn to is Keith Block, M.D. "I believe in Keith's program and would head to the Block Center if I were facing a diagnosis of cancer. It is where I have and will continue to send my friends and family," said Dr. Weil.

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

Study aims to clarify expression patterns of CD24 in NSCLC

The May edition of the Journal of Thoracic Oncology features a study aimed to clarify expression patterns of a novel cancer biomarker, CD24, in non-small cell lung carcinomas (NSCLC) and to correlate the findings to clinicopathologic variables, such as performance status, age, gender and prognostic significance.

6 May 2010

VEGF is key target for new anti-angiogenesis drugs, Spanish team reports

Analyzing the expression of particular genes in lung cancers could soon allow researchers to identify groups of patients who are likely to benefit most from treatment with angiogenesis-inhibitor drugs, a Spanish team reports.

6 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Approval of personalized therapy for lung cancer in Europe will change way of treatment

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work, a leading expert said today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

4 May 2010

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN N.V. today announced the results of operations for its quarter ended March 31, 2010. Net sales were at the high end of, and adjusted earnings per share for the first quarter 2010 exceeded the guidance provided by the Company on February 9, 2010.

From QIAGEN Manchester Limited 4 May 2010

Protein test to determine response of lung cancer patients to erlotinib

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

3 May 2010

SGB procedure holds potential promise for PTSD treatment

Walter Reed Army Medical Center in Bethesda, MD, has published case reports detailing the successful treatment of combat-related post-traumatic stress disorder with a stellate ganglion block.

3 May 2010

Report shows increasing rates of AMD among Asians

The May issue of Ophthalmology, the journal of the American Academy of Ophthalmology, includes a surprising, first report on increasing rates of age-related macular degeneration among Asians, and describes an innovative "bypass" laser surgery that may help many people with central retinal vein occlusion avoid serious vision loss.

3 May 2010

Researchers discover a new driving force behind cancer growth

Researchers from the University of Leeds, UK, the Charit- University Medical School and the Max Delbr-ck Centre for Molecular Medicine (MDC) in Berlin, Germany, have discovered a new driving force behind cancer growth.

3 May 2010